P501: Communicating Needs and Features of IBD Experiences (CONFIDE) Survey: Prevalence and patients’ experience of moderate-to-severe Crohn@E@s disease symptoms in CanadaECCO'24Year: 2024
Authors: Jairath, V.(1)*;Glass, J.(2);Braun, M.(2);Bessissow, T.(3);Gibble, T.(4);Atkinson, C.(5); Ellis, H.(5);Dewar, T.(5);Panaccione, R.(6);
(1)Western University & London Health Sciences Centre, Departments of Medicine- Epidemiology and Biostatistics, London, Canada;(2)Eli Lilly and Company, Immunology, Toronto, Canada;(3)McGill University Health Centre, Division of Gastroenterology and Hepatology, Montreal, Canada;(4)Eli Lilly and Company, Immunology, Indianapolis, United States;(5)Adelphi Real World, Statistics, Bollington, United Kingdom;(6)University of Calgary Cumming School of Medicine, Gastroenterology, Calgary, Canada;
P502: Multimodal profiling of peripheral blood identifies proliferating circulating effector CD4 T cells as predictors for response to integrin alpha4 beta7-blocking therapy in patients with Inflammatory Bowel DiseaseECCO'24Year: 2024
Authors: Horn, V.(1,2);Cancino, C.(1,2);Steinheuer, L.(3);Obermayer, B.(4);Fritz, K.(1,2);Siegmund, B.(1);Thurley, K.(3);Hegazy, A.N.(1,2)*;
(1)Charité – Universitätsmedizin Berlin- corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Gastroenterology- Infectious Diseases and Rheumatology, Berlin, Germany;(2)Deutsches Rheuma-Forschungszentrum- ein Institut der Leibniz-Gemeinschaft, Inflammatory Mechanisms, Berlin, Germany;(3)University Hospital Bonn, Institute for Experimental Oncology- Biomathematics Division, Bonn, Germany;(4)Berlin Institute of Health at Charité – Universitätsmedizin Berlin, Core Unit Bioinformatics, Berlin, Germany;TRR241 IBDome Consortium
P503: Differentiation of patients with IBD at increased risk of CRC using UR-CARE: A Single Centre ExperienceECCO'24Year: 2024
Authors: Valkov, H.(1)*;Lyutakov, I.(1);Peneva, P.(1);Vladimirov, B.(1);Penchev, P.(1);
(1)Clinic of Gastroenterology- University Hospital @D@Tsaritsa Yoanna-ISUL@D@, Department of Gastroenterology- Medical University – Sofia- Bulgaria, Sofia, Bulgaria;
P504: Prevalence of gastrointestinal infections in ulcerative colitis patients assessed with QIASTAT-DX® GASTROINTESTINAL PANEL 2ECCO'24Year: 2024
Authors: Anolli, M.P.(1);Liporace, M.F.(1);Noviello, D.(1)*;Piazza O Sed, N.(2);Conforti, F.(2);Amoroso, C.(2);Teri, A.(3);Cariani, L.(3);Caprioli, F.(1);Vecchi, M.(1);
(1)University of Milan, Department of Pathophysiology and Transplantation, Milan, Italy;(2)Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Division of Gastroenterology and Endoscopy, Milan, Italy;(3)Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Microbiology Unit, Milan, Italy;
P505: Accelerating Crohn@E@s Disease clinical trials using generative artificial intelligenceECCO'24Year: 2024
Authors: Turner , M.(1);Millar , S.(1);Kusiak , C.(1);Fuller , F.D.(2)*;Walsh , J.(2);Zhuang , R.(2);
(1)Unlearn.ai, Clinical Applications, San Francisco, United States;(2)Unlearn.ai, Machine Learning, San Francisco, United States;
P506: Prevalance of the osteoporosis/osteopenia and related factors in patients with inflammatory bowel disease : An observational single-center studyECCO'24Year: 2024
Authors: Celebi, G.(1)*;Ekici, R.(1);Buyukturan, G.(1);Gul Aydın, E.(1);Uygun, A.(1);
(1)Gulhane Training and Research Hospital, Department of Gastroenterology, Ankara, Turkey;
P507: Can systematic upper gastrointestinal endoscopy benefit patients with Inflammatory Bowel Disease?ECCO'24Year: 2024
Authors: Koulali, H.(1)*;Zazour, A.(2);Elmqaddem, O.(2);Ismaili, Z.(2);Kharrasse, G.(2);
(1)Digestive Disease Research Laboratory- Medical School- Mohammed first University- Oujda- Morocco, Department of Hepato-gatsroenterology- Mohammed VI University hospital center- Oujda- Morocco, Oujda, Morocco;(2)Digestive Disease Research Laboratory- Medical School- Mohammed first University- Oujda- Morocco, Department of Hepato-gastroenterology- Mohammed VI University hospital center- Oujda- Morocco, Oujda, Morocco;
P508: Pre-operative exposure to tofacitinib is as safe as biologics in patients with ulcerative colitis undergoing colectomy: a multicentre observational studyECCO'24Year: 2024
Authors: Dragoni, G.(1)*;Innocenti, T.(1);Amiot, A.(2);Castiglione, F.(3);Melotti, L.(4);Festa, S.(5);Savarino, E.V.(6);Truyens, M.(7);Argyriou, K.(8);Noviello, D.(9);Molnar, T.(10);Bouillon, V.(11);Bezzio, C.(12);Eder, P.(13);Fernandes, S.(14);Kagramanova, A.(15);Armuzzi, A.(16);Oliveira, R.(17);Viola, A.(18);Ribaldone, D.G.(19);Drygiannakis, I.(20);Viganò, C.(21);Calella, F.(22);Gravina, A.G.(23);Pugliese, D.(24);Chaparro, M.(25);Ellul, P.(26);Vieujean, S.(27);Milla, M.(1);Caprioli, F.(9);
(1)Careggi University Hospital, Department of Gastroenterology- IBD Referral Centre, Florence, Italy;(2)Henri Mondor University Hospital- Paris Est-Creteil University, Department of Gastroenterology, Creteil, France;(3)@D@Federico II@D@ University of Naples, Department of Clinical Medicine and Surgery, Naples, Italy;(4)Alma Mater Studiorum University of Bologna, Department of Medical and Surgical Sciences, Bologna, Italy;(5)@D@San Filippo Neri@D@ Hospital, IBD Unit, Rome, Italy;(6)University of Padova, Department of Surgery- Oncology and Gastroenterology, Padua, Italy;(7)Ghent University Hospital, Department of Gastroenterology, Ghent, Belgium;(8)University Hospital of Larisa, Department of Gastroenterology, Larissa, Greece;(9)Fondazione IRCCS Cà Granda- Ospedale Maggiore Policlinico di Milano, Gastroenterology and Endoscopy Unit, Milan, Italy;(10)Albert Szent-Györgyi Medical School- University of Szeged, Department of Gastroenterology, Szeged, Hungary;(11)Erasme University Hospital, Department of Gastroenterology, Brussels, Belgium;(12)ASST Rhodense, Gastroenterology Unit, Rho- Milan, Italy;(13)Poznań University of Medical Sciences- Heliodor Święcicki University Hospital, Department of Gastroenterology- Dietetics and Internal Medicine, Poznań, Poland;(14)Hospital de Santa Maria- Centro Hospitalar Universitário de Lisboa Norte, Department of Gastroenterology and Hepatology, Lisboa, Portugal;(15)Moscow Clinical Scientific Center named after A.S. Loginov, Gastroenterology, Moscow, Russian Federation;(16)IRCCS Humanitas Research Hospital, IBD Center, Rozzano- Milan, Italy;(17)Algarve University Hospital Centre – Portimão Unit, Gastroenterology Department, Algarve, Portugal;(18)University of Messina, IBD-Unit- Department of Clinical and Experimental Medicine, Messina, Italy;(19)University of Turin, Division of Gastroenterology- Department of Medical Sciences, Turin, Italy;(20)University Hospital of Heraklion, Department of Gastroenterology, Heraklion, Greece;(21)University of Milano-Bicocca, Division of Gastroenterology- Center for Autoimmune Liver Diseases- Department of Medicine and Surgery, Monza, Italy;(22)Azienda USL Toscana Centro- Ospedale “San Giuseppe”, SOC Gastroenterologia ed endoscopia digestiva, Empoli, Italy;(23)University of Campania “Luigi Vanvitelli”, Hepatogastroenterology Unit- Department of Precision Medicine, Naples, Italy;(24)Fondazione Policlinico Universitario @D@A. Gemelli@D@ IRCCS, CEMAD- IBD Unit- Dipartimento di Scienze Mediche e Chirurgiche, Rome, Italy;(25)Hospital Universitario de La Princesa- Instituto de Investigación Sanitaria Princesa IIS-Princesa- Universidad Autónoma de Madrid UAM- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Gastroenterology Unit, Madrid, Spain;(26)Mater Dei Hospital, Department of Medicine- Division of Gastroenterology, Msida, Malta;(27)University Hospital CHU of Liège, Hepato-Gastroenterology and Digestive Oncology, Liège, Belgium;@D@TOFA-poSTOP@D@ Study Group
P509: Upadacitinib improves symptomatic responses in patients with moderately to severely active Crohn’s diseaseECCO'24Year: 2024
Authors: Blumenstein, I.(1)*;Torres, J.(2,3);Ma, C.(4,5);Lindsay, J.O.(6);Ungaro, R.(7);Thin, L.(8,9);Lacerda, A.P.(10);Anyanwu, S.I.(10);Garrison, A.(10);Ford , S.(10);Louis, E.(11);
(1)Goethe-University Hospital, Department of Internal Medicine 1, Frankfurt, Germany;(2)Hospital Beatriz Ângelo, Division of Gastroenterology, Loures, Portugal;(3)Hospital da Luz Division of Gastroenterology, Faculdade de Medicina Universidade de Lisboa, Lisboa, Portugal;(4)University of Calgary, Division of Gastroenterology and Hepatology, Calgary, Canada;(5)University of Calgary, Department of Community Health Sciences, Calgary, Canada;(6)Queen Mary University of London, Centre for Immunobiology- Barts and the London School of Medicine and Dentistry, London, United Kingdom;(7)Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York, United States;(8)University of Western Australia, Department of Internal Medicine- UWA Medical School, Perth, Australia;(9)Fiona Stanley Hospital, Department of Gastroenterology, Murdoch, Australia;(10)AbbVie, Inc., North Chicago, United States;(11)University Hospital CHU of Liège, Department of Hepato-Gastroenterology and Digestive Oncology, Liège, Belgium;
P510: Relapse rate following withdrawal of vedolizumab and ustekinumab in patients with inflammatory bowel disease. The VEDUST-EXIT studyECCO'24Year: 2024
Authors: Albshesh, A.(1)*;Kucha , P.(2);Mahajna, H.(1,3);Amiot , A.(4);Abitbol, C.M.(1);Eder , P.(5);Imperatore , N.(6);Krznaric , Z.(7);Zaborowska, M.(2);Zagórowicz , E.(2);Carbonnel , F.(4);Zittan , E.(3);Ben-Horin, S.(1);Kopylov, U.(1);
(1)Sheba Medical Center and Sackler School of Medicine- Tel-Aviv University, Department of Gastroenterology, Ramat Gan, Israel;(2)The Maria Sklodowska-Curie National Research Institute of Oncology Centre of Postgraduate Medical Education, Department of Gastroenterology- Hepatology and Clinical Oncology, Warsaw, Poland;(3)Emek Medical Center, The Abraham and Sonia Rochlin IBD Unit- Department of Gastroenterology, Afula, Israel;(4)Assistance Publique-Hôpitaux de Paris- Université Paris Saclay, Service de Gastroentérologie CHU Bicêtre, Paris, France;(5)Poznań University of Medical Sciences- Heliodor Święcicki Hospital, Department of Gastroenterology- Dietetics and Internal Medicine, Poznan, Poland;(6)Santa Maria delle Grazie Hospital, Gastroenterology and Endoscopy Unit, Pozzuoli Naples, Italy;(7)University Hospital Zagreb, Department of Internal Medicine- Clinical Unit of Clinical Nutrition-, Zagreb, Croatia;
P511: Short-term real-world effectiveness and safety of granulocyte and monocyte adsorptive apheresis (GMA) in patients with inflammatory bowel disease: GRACE Study.ECCO'24Year: 2024
Authors: Rodríguez-Lago, I.(1)*;Ginard, D.(2);Díaz Molina, R.J.(2);Vicuña, M.(3);Domenech, E.(4,5);Abanades, M.(6);Moralejo Lozano, O.(6);Bastida, G.(7);Sánchez Capilla, A.D.(8);Iglesias, E.(9);Rancel-Medina, F.(10);Blasco, M.D.M.(11);Bosca-Watts, M.(12);Calvo Iñiguez, M.(13);Herrera deGuisé, C.(14);Leo, E.(15);Viejo Almanzor, A.(16);Hernández Ramirez, V.(17);Suárez Ferrer, C.(18);Quilez Pérez, L.(19);Muñoz, M.(20);Fernández Pérez, F.(21);Huguet, J.M.(12);Fradejas, P.(22);López Ramos, C.(22);Fuentes Coronel, A.M.(22);Reygosa Castro, C.(23);Rull Murillo, N.(24);Zapico, P.(25);Cabriada, J.L.(1);
(1)Hospital Universitario Galdakao-Usansolo, Gastroenterology, Galdakao, Spain;(2)Hospital Universitario Son Espases, Gastroenterology, Palma de Mallorca, Spain;(3)Hospital Universitario de Navarra, Gastroenterology, Pamplona, Spain;(4)Hospital Universitari Germans Trias i Pujol, Gastroenterology, Badalona, Spain;(5)Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestiva, Gastroenterology, Barcelona, Spain;(6)Hospital Universitario de Toledo, Gastroenterology, Toledo, Spain;(7)Hospital Universitario y Politécnico La Fe, Gastroenterology, Valencia, Spain;(8)Hospital Universitario Virgen de las Nieves, Gastroenterology, Granada, Spain;(9)Hospital Universitario Reina Sofía- Instituto Maimónides de Investigación Biomédica de Córdoba IMIBIC, Disgestive Service, Cordoba, Spain;(10)Hospital Río Carrión- Complejo Asistencial de Palencia CAUPA, Gastroenterology, Palencia, Spain;(11)Hospital Universitario Puerta de Hierro, Gastroenterology, Madrid, Spain;(12)Hospital General Universitario de Valencia, Gastroenterology, Valencia, Spain;(13)Hospital Universitario San Pedro, Gastroenterology, Logroño, Spain;(14)Hospital Vall d@E@Hebron, Gastroenterology, Barcelona, Spain;(15)Hospital Universitario Virgen del Rocío, Gastroenterology, Sevilla, Spain;(16)Hospital Universitario Puerta del Mar, Gastroenterology, Cádiz, Spain;(17)Hospital Álvaro Cunqueiro, Gastroenterology, Vigo, Spain;(18)Hospital Universitario La Paz, Gastroenterology, Madrid, Spain;(19)Hospital Universitario San Jorge de Huesca, Gastroenterology, Huesca, Spain;(20)Hospital General Universitario de Castellón, Gastroenterology, Castellón de la Plana, Spain;(21)Hospital Universitario Costa del Sol, Gastroenterology, Marbella, Spain;(22)Hospital Virgen de la Concha, Gastroenterology, Zamora, Spain;(23)Complejo Hospitalario Universitario de Canarias, Gastroenterology, La Laguna, Spain;(24)Hospital Son Llàtzer, Gastroenterology, Palma de Mallorca, Spain;(25)Adacyte Therapeutics, Gastroenterology, Barcelona, Spain;
P512: Early proactive therapeutic drug monitoring with ustekinumab therapy in paediatric Crohn@E@s DiseaseECCO'24Year: 2024
Authors: Ricciuto, A.(1)*;McKay, H.(2);deBruyn, J.(3);Crowley, E.(4);Church, P.(2);Huynh, H.(5);Otley, A.(6);Shaikh, A.(2);El-Matary, W.(7);Wine, E.(5);Walters, T.(2);Griffiths, A.(2);
(1)The Hospital for Sick Children, Division of Gastroenterology, Toronto, Canada;(2)The Hospital for Sick Children, Division of Gastroenterology Hepatology and Nutrition, Toronto, Canada;(3)University of Calgary, Division of Gastroenterology Hepatology and Nutrition, Calgary, Canada;(4)London Health Sciences Centre, Division of Gastroenterology Hepatology and Nutrition, London, Canada;(5)University of Alberta, Division of Gastroenterology Hepatology and Nutrition, Edmonton, Canada;(6)IWK Health Centre, Division of Gastroenterology Hepatology and Nutrition, Halifax, Canada;(7)University of Manitoba, Division fo Gastroenterology Hepatology and Nutrition, Winnipeg, Canada;
P513: Clinical efficacy and durability of subcutaneous infliximab in patients with inflammatory bowel disease after switching from intravenous in a Korean multicenter prospective cohort studyECCO'24Year: 2024
Authors: Kim, K.(1)*;Hong, S.N.(2);Kang, S.B.(3);Lee, K.M.(4);Koo, J.S.(5);Jung, Y.(6);Lee , B.J.(7);Yoon, H.(8);Kim, H.W.(9);Lim, Y.J.(10);Lee, H.S.(11);Lee, Y.J.(12);Lee, J.(13);Lee, C.K.(14);Shin, S.Y.(15);Moon, J.M.(15);Seo, J.(16);Choi , C.H.(17);
(1)Chung-Ang University Hospital, Department of gastroenterology, Seoul, Korea- Republic Of;(2)Samsung Medical Center- Sungkyunkwan University School of Medicine, Department of Medicine, Seoul, Korea- Republic Of;(3)Daejeon St. Mary’s Hospital- The Catholic University of Korea, Division of Gastroenterology- Department of Internal medicine-, Daejeon, Korea- Republic Of;(4)St. Vincent@E@s Hospital- College of Medicine- The Catholic University of Korea, Department of Internal Medicine, Suwon, Korea- Republic Of;(5)Korea University College of Medicine- Ansan- Korea, Department of Internal Medicine, Ansan, Korea- Republic Of;(6)Soonchunhyang University College of Medicine, Department of Internal Medicine, Cheonan, Korea- Republic Of;(7)Korea University College of Medicine, Department of Internal medicine, Seoul, Korea- Republic Of;(8)Seoul National University Bundang Hospital, Department of Internal Medicine, Seongnam, Korea- Republic Of;(9)Pusan National University Yangsan Hospital- Pusan National University College of Medicine, Department of Internal Medicine, Yangsan, Korea- Republic Of;(10)Dongguk University Ilsan Hospital, Department of Internal Medicine, Goyang, Korea- Republic Of;(11)Kyungpook National University School of Medicine, Department of Internal Medicine, Daegu, Korea- Republic Of;(12)Keimyung University School of Medicine, Department of Internal Medicine, Daegu, Korea- Republic Of;(13)Chosun University College of Medicine, Department of Internal Medicine, Gwangju, Korea- Republic Of;(14)Kyung Hee University School of Medicine, Department of internal medicine, Seoul, Korea- Republic Of;(15)Chung-Ang University Gwangmyeong Hospital, Department of internal medicine, Gwangmyeong, Korea- Republic Of;(16)Chung-Ang University Hospital, Department of internal medicine, Seoul, Korea- Republic Of;(17)Chung-Ang University Hospital, Department of internal mediciine, Seoul, Korea- Republic Of;
P514: Beyond the First Attempt: A Multi-Centre UK Analysis of Second JAK Inhibitor Use in Ulcerative ColitisECCO'24Year: 2024
Authors: Danso, Y.(1)*;Radia, C.(2);Kent, A.(2);Harrow, P.(3);Pavlidis, P.(2);Selinger, C.(4);Samaan, M.(5);Patel, K.(6);Kumar, R.(7);Fraser, A.(8);Allah-Ditta, M.(9);Pillay, L.(10);Bishara, M.(11);Campbell, R.(12);Patel, C.(5);Elford, A.(13);Dong , C.(14);Sethi-Arora , K.(15);Davis, E.(16);Hale, M.(17);Yeung, K.(18);Mehta, S.(6);Rees, F.(19);George, B.(20);Yeo, J.H.(3);Harvey, P.(21);Sawan , N.J.(22);Lees, C.(13);Walsh, A.(16);Rawcliffe, M.(17);Pollok, R.(6);Speight, A.(14);Al-zarrad, D.(18);Chhabra , P.(9);Raine, T.(10);Limdi, J.(15);Ahmad, T.(11);Toft, J.(3);Hussain, M.A.(7);Kok, K.(1);
(1)Barts and the London NHS Trust, Gastroenterology, London, United Kingdom;(2)Kings College NHS Foundation Trust, Gastroenterology, London, United Kingdom;(3)University College London Hospitals NHS Foundation Trust, Gastroenterology, London, United Kingdom;(4)Leeds Teaching Hospitals NHS Trust., Gastroenterology, Leeds, United Kingdom;(5)Guy@E@s and St Thomas@E@ NHS Foundation Trust, Gastroenterology, London, United Kingdom;(6)St George’s Hospital, Gastroenterology, London, United Kingdom;(7)University Hospitals Birmingham NHS Foundation Trust, Gastroenterology, Birmingham, United Kingdom;(8)Bristol Royal Infirmary, Gastroenterology, Bristol, United Kingdom;(9)Calderdale and Huddersfield Foundation Trust, Gastroenterology, Huddersfield, United Kingdom;(10)Cambridge University Hospitals NHS Foundation Trust, Gastroenterology, Cambridge, United Kingdom;(11)Royal Devon University Hospitals NHS Foundation Trust, Gastroenterology, Exeter, United Kingdom;(12)Queen Elizabeth University Hospital, Gastroenterology, Glasgow, United Kingdom;(13)NHS Lothian, Gastroenterology, Edinburgh, United Kingdom;(14)Royal Victoria Infirmary- Newcastle upon Tyne Hospitals, Gastroenterology, Newcastle, United Kingdom;(15)Northern Care Alliance NHS Foundation Trust, Gastroenterology, Manchester, United Kingdom;(16)Oxford University Hospitals, Gastroenterology, Oxford, United Kingdom;(17)Sheffield Teaching Hospitals NHS Foundation Trust., Gastroenterology, Sheffield, United Kingdom;(18)St Marks Hospital, Gastroenterology, London, United Kingdom;(19)University Hospitals Sussex, Gastroenterology, Sussex, United Kingdom;(20)Torbay and South Devon- Torbay Hospital, Gastroenterology, Torquay, United Kingdom;(21)The Royal Wolverhampton NHS Trust, Gastroenterology, Wolverhampton, United Kingdom;(22)Queen Elizabeth Hospital- Woolwich, Gastroenterology, London, United Kingdom;
P515: Exclusive enteral nutrition downstages complicated Crohn’s disease prior to surgical resection: A feasibility studyECCO'24Year: 2024
Authors: Zuk, D.(1)*;Jaksic, D.(1);Andersson, S.(2);Soop, M.(2);
(1)Ersta Hospital, Department of Surgery, Stockholm, Sweden;(2)Karolinska University Hospital, Department of Inflammatory Bowel Disease and Intestinal Failure Surgery, Stockholm, Sweden;
P516: Subcutaneous infliximab cut-off points in a large cohort of Spanish patients with inflammatory bowel disease and factors associated with long-term outcomes.ECCO'24Year: 2024
Authors: Iborra, M.(1)*;Caballol, B.(2);Garrido, A.(1);Huguet, J.M.(3);Mesonero, F.(4);Ponferrada, A.(5);Arias-García, L.(6);Boscá-Watts, M.M.(7);Fernández-Prada, S.J.(8);Brunet-Mas , E.(9);Gutierrez-Casbas, A.(10);Ordás, I.(2);Ruiz, L.(3);García de la Filia, I.(4);Escobar Ortiz, J.(5);Sicilia, B.(6);Ricart, E.(2);Nos, P.(1);
(1)La Fe University and Polytechnic Hospital, Department of Gastroenterology, Valencia, Spain;(2)Hospital Clínic Barcelona. IDIBAPS. CIBER-EHD., Unidad de enfermedad inflamatoria intestinal., Barcelona, Spain;(3)Hospital General Universitario de Valencia., Gastroenterology, Valencia, Spain;(4)Hospital Universitario Ramón y Cajal., Gastroenterology, Madrid, Spain;(5)Hospital Universitario Infanta Leonor., Gastroenterology, Madrid, Spain;(6)Hospital Universitario de Burgos, Gastroenterology, Burgos, Spain;(7)Hospital Clínico Universitario de Valencia, Gastroenterology, Valencia, Spain;(8)Hospital Rio Hortega, Gastroenterology, Valladolid, Spain;(9)Parc Taulí Hospital Universitari. Institut d’Investigació i Innovació Parc Taulí I3PT-CERCA and Departament de Medicina- Universitat Autònoma de Barcelona CIBERehd- Instituto de Salud Carlos III., Gastroenterology, Sabadell, Spain;(10)Hospital General Universitario de Alicante, Gastroenterology, Alicante, Spain;
P517: Endoscopic mucosal resection (EMR) in treatment of colitis associated neoplasia (CAN): a single-centre experience from Leuven, BelgiumECCO'24Year: 2024
Authors: Panic, N.(1)*;Vermeire, S.(2);Ingrid, D.(3);Joao, S.(2);Tarabar, D.(4);Bisschops, R.(2);
(1)University Clinic @D@Dr Dragisa Misovic-Dedinje@D@, Digestive Endoscopy Department, Beograd, Serbia;(2)Targid Ku Leuven, University Hospitals Leuven deot of Gastroenterology and Hepatology., Leuven, Belgium;(3)Targid Ku Leuven, University Hospitals Leuven deot of Gastroenterology and Hepatology, Leuven, Belgium;(4)University Clinic @D@Dr Dragisa Misovic-Dedinje@D@, Center for Inflammatory Bowel Disease, Belgrade, Serbia;
P518: Dietary and non-dietary predictors of treatment response to adalimumab in anti-TNFα-naïve adults with Crohn’s diseaseECCO'24Year: 2024
Authors: Jatkowska, A.(1)*;White, B.(1);Campbell, I.(1);Brownson, E.(2);Short, B.(1);Clowe, J.(1);Seenan, J.P.(2);Gaya, D.R.(3);Din, S.(4);Ho, G.T.(4);Robertson, E.(5);Mowat, C.(6);Milling, S.(7);MacDonald, J.(2);Gerasimidis, K.(1);
(1)University of Glasgow, Human Nutrition, Glasgow, United Kingdom;(2)Queen Elizabeth University Hospital, Department of Gastroenterology, Glasgow, United Kingdom;(3)Glasgow Royal Infirmary, Department of Gastroenterology, Glasgow, United Kingdom;(4)Western General Hospital, Department of Gastroenterology, Edinburgh, United Kingdom;(5)University Hospital Hairmyres, Department of Gastroenterology, Lanarkshire, United Kingdom;(6)Ninewells Hospital, Department of Gastroenterology, Dundee, United Kingdom;(7)University of Glasgow, School of Infection and Immunity, Glasgow, United Kingdom;
P519: Assessment of anal sphincter complex in pregnant patients with non-active perianal Crohns diseaseECCO'24Year: 2024
Authors: Bar-Gil Shitrit, A.(1)*;Mishael , T.(2);Reiss Mintz, H.(3);Goldenberg , R.(4);Freund, M.R.(5);Yellinek, S.(5);
(1)Shaare Zedek Medical Center, Department of Gastroenterology and Digestive Diseases, Jerusalem, Israel;(2)Shaare Zedek Medical Center, Gynecology, Jerusalem, Israel;(3)Mayanei Hayeshua Medical Center, Gastroenterology, Bnei Brak, Israel;(4)Shaare Zedek Medical Center, Gastroenterology, Jerusalem, Israel;(5)Shaare Zedek Medical Center, General Surgery, Jerusalem, Israel;
P520: Preferences towards treatment attributes among patients with Crohn’s disease and ulcerative colitis in Argentina, Australia, Brazil, Saudi Arabia and Taiwan: a discrete choice experimentECCO'24Year: 2024
Authors: Argollo, M.(1)*;An , Y.K.(2);Balderramo, D.(3);Nahla, A.(4);Kuo, C.J.(5);Fadeeva, O.(6);Uy, E.(6);
(1)Federal University of São Paulo, Department of Gastroenterology, São Paulo, Brazil;(2)Mater Hospital Brisbane, Inflammatory Bowel Disease, Brisbane, Australia;(3)Instituto Universitario de Ciencias Biomédicas de Córdoba, Servicio de Gastroenterología y Endoscopia Digestiva- Hospital Privado Universitario de Córdoba, Córdoba, Argentina;(4)King Saud University College of Medicine, Department of Medicine, Riyadh, Saudi Arabia;(5)Chang Gung Memorial Hospital, Department of Gastroenterology and Hepatology, Linkou, Taiwan;(6)Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals, Singapore, Singapore;